Microglial subtypes in neurodegeneration — friend vs foe¶
Notebook ID: nb-SDA-2026-04-17-gap-microglial-subtypes-pharmaco-20260417000001 · Analysis: SDA-2026-04-17-gap-microglial-subtypes-pharmaco-20260417000001
Domain: neurodegeneration · Date: 2026-04-17
Research Question¶
Analyze the spectrum of microglial activation states (DAM, homeostatic, inflammatory) and their distinct roles in AD, PD, and ALS. Identify pharmacological targets for shifting microglia toward protective phenotypes.
Debate Summary¶
Debate transcript not available for this analysis.
Hypotheses Ranked by Composite Score¶
Total hypotheses: 7
| Title | Composite | Confidence | Novelty | Feasibility | Impact |
|---|---|---|---|---|---|
| TREM2-APOE Axis Manipulation via APOE Lipidation for DAM Recruitment | 0.685 | 0.78 | 0.58 | 0.68 | 0.72 |
| CX3CL1-CX3CR1 Mimetic Therapy for Neuroprotection | 0.635 | 0.62 | 0.62 | 0.68 | 0.7 |
| CD38 Inhibition for NAD+ Restoration and Microglial Senescence Prevention | 0.575 | 0.55 | 0.72 | 0.42 | 0.58 |
| CSF1R Partial Agonism Combined with TREM2 Activation for ALS Neuroprotection | 0.535 | 0.58 | 0.68 | 0.32 | 0.62 |
| ITGAX/CD11c Targeting to Eliminate Pro-inflammatory DAM in ALS | 0.408 | 0.48 | 0.72 | 0.32 | 0.38 |
| PU.1 Degradation via PROTAC for Inflammatory Microglial Polarization | 0.408 | 0.45 | 0.8 | 0.28 | 0.38 |
| IRP2-Iron Axis Modulation to Reduce Ferroptotic Vulnerability | 0.398 | 0.48 | 0.62 | 0.25 | 0.4 |
Knowledge Graph Edges¶
Total edges: 12
| Source | Relation | Target | Evidence |
|---|---|---|---|
| TREM2 | signals through | TYROBP | 0.5 |
| APOE4 | impairs | TREM2-dependent clustering | 0.5 |
| ABCA1 | lipidates | APOE | 0.5 |
| CX3CR1 | suppresses | NLRP3 inflammasome | 0.5 |
| CX3CR1 | regulates | P2Y12 | 0.5 |
| CD38 | depletes | NAD+ | 0.5 |
| CSF1R | maintains | microglial survival | 0.5 |
| SPI1/PU.1 | regulates | TREM2 | 0.5 |
| IREB2/IRP2 | represses | FTH1 | 0.5 |
| ITGAX/CD11c | marks | DAM subset | 0.5 |
| TREM2 | coordinates | iron accumulation | 0.5 |
| CX3CL1 | engages | CX3CR1 | 0.5 |
Key Citations¶
No citations found for this analysis.